01—Abstract
Summary
Summary of the 8-K filed August 29, 2025. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc. (NYSE: DD) entered into a Transaction Agreement on August 29, 2025 with Arclin, a portfolio company of an affiliate of TJC, L.P., to sell its Aramids business (Kevlar® and Nomex®) in a transaction valuing the business at approximately $1.8 billiona.
Subject to customary closing conditions, including regulatory approvals, DuPont will receive pre-tax cash proceeds of approximately $1.2 billionb, subject to customary transaction adjustments, a $300 million note receivable, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million, expected to represent an approximate 17.5% stake at closing. According to the accompanying press release, the transaction is expected to close in the first quarter of 2026, and Arclin has fully committed financing. Management states the divestiture further streamlines the new DuPont portfolio, enhances its strategic focus, and increases the growth and margin profile, with the cash proceeds at close to be redeployed to drive value creation.
The Aramids business, which has about 1,900 employees and five manufacturing sites, generated net sales of $1.3 billionc in 2024. The press release also states that the Aramids divestiture will not affect the intended separation of DuPont's electronics business (Qnity), which remains on track for a November 1, 2025 spin-off. The filing notes that the information is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Agreement to sell the Aramids business (Kevlar® and Nomex®) to Arclin, a TJC-affiliated portfolio company, at a valuation of approximately $1.8 billion
- DuPont to receive approximately $1.2 billion in pre-tax cash proceeds at close, subject to customary transaction adjustments
- Additional consideration includes a $300 million note receivable and a non-controlling common equity interest in the future Arclin company valued at $325 million (approximately 17.5% stake at closing)
- Transaction expected to close in the first quarter of 2026, subject to customary closing conditions and regulatory approval; Arclin has fully committed financing
- Aramids business generated net sales of $1.3 billion in 2024, with about 1,900 employees and five manufacturing sites
- Divestiture does not affect the Qnity electronics spin-off, which remains on track for November 1, 2025
- Management states the transaction streamlines the portfolio, increases its growth and margin profile, and allows shareholders to participate in Arclin's future growth
03—Questions
Frequently Asked Questions
What is DuPont selling and for how much?
DuPont agreed to sell its Aramids business, which makes Kevlar® and Nomex®, to Arclin in a transaction valuing the business at approximately $1.8 billion.
What will DuPont receive at closing?
At closing, DuPont will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a $300 million note receivable, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million, expected to be about a 17.5% stake.
When is the transaction expected to close and what could affect it?
The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals set forth in the Transaction Agreement.
Does this transaction affect the planned electronics spin-off?
According to the press release, the Aramids divestiture will not impact DuPont's intended separation of its electronics business (Qnity), which remains on track for a November 1, 2025 spin-off.
How is management describing the strategic rationale?
Management states the divestiture further streamlines the new DuPont portfolio, enhances its strategic focus, increases its growth and margin profile, and allows DuPont shareholders to participate in Arclin's growth potential through the retained equity interest.
04—Continue